Shakeel 
The Abu Dhabi Stem Cells Centre (ADSCC) has achieved another as they have successfully treated milestone by far, a total of six cancer patients with blood malignancies. These patients are also on their way to recovering well.
This milestone was achieved due to the implementation of the Abu Dhabi Bone Marrow Transplant program (AD-BMT) which was first introduced in July 2020.
Initiated by ADSCC, the AD-BMT programme was established to provide the highest standard of care in the field of Hematopoietic Stem Cells Transplant.
Admittance into the programme started in early August 2020, and has included patients with different types of blood malignancies including Multiple Myeloma, Plasma Cell Leukemia, Large Diffuse B-Cell Lymphoma and Hodgkin Lymphoma. The treatment duration has varied for each patient, ranging from 19 days to up to one month.
Abu Dhabi Stem Cells Centre continues to successfully treat cancer patients using Bone Marrow Transplant Treatment.
Read More | PPP demands Election Commission to reschedule senate polls in Pakistan
So far, a total of six patients with blood malignancies have been successfully treated
ADSCC has been treating COVID-19 patients with stem cells sourced from the patient’s blood, by returning the cells back into the patient’s lungs as a fine mist through a nebulizer, a machine that helps a patient breathe in medicine through a mask or mouthpiece.
Abu Dhabi Stem Cells Center (ADSCC) is an Abu Dhabi-based specialist healthcare center focused on cell therapy and regenerative medicine, as well as delivering cutting-edge research on stem cells in the region. The Center was founded in March 2019 to meet growing domestic and regional demand for highly specialized medical services and treatments.
ADSCC is equipped with the latest technologies, medical devices which are unique to the region, and a team of internationally recognized doctors working hand in hand with researchers, ADSCC is the first of its kind in the UAE. ADSCC specialties include immunology, hematology, clinical stem cell therapy, molecular biology, immunotherapy, orthopedics, and urology – amongst others.
